[Synthetic human calcitonin in Paget's disease of bone and osteoporosis (author's transl)].
Synthetic human calcitonin was used in the treatment of 26 patients over a period of 1-14 months. 17 patients had Paget's disease of the bone, 6 postmenopausal osteoporosis and 3 Sudeck's syndrome. Subjective improvement (reduction of pain, improvement of mobility) was found in 15 patients with Paget's disease, in 4 females with postmenopausal osteoporosis and in all 3 patients with Sudeck's syndrome. Radiographic improvement of bone changes developed only very slowly. These results were confirmed by diminution of the exchangeable calcium pool indicating reduction of rates of osseous degradation. Calcitonin tolerance was acceptable. Transitory nausea and occasional vomiting occurred in 3 patients.
D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010001:Osteitis Deformans / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D002116:Calcitonin
Synthetisches Human-Calcitonin bei Osteodystrophia deformans (Paget) und Osteoporose.